Thursday, August 13, 2026
← Back to archivePolicy
Policy•STAT News•Aug 13, 2026
Opinion: I’ve seen what life is like without vaccines. Americans need to understand what they save us from
background ▾
- •Executive order mandates separation of combination vaccines (e.g., MMR into three separate shots) and pushes states to abandon school vaccination requirements, directly undermining efficient immunization schedules with no public health evidence supporting these changes.
- •Real-world consequences emerging: measles cases at 35-year high (2,465 cases) as kindergarten vaccination coverage falls below herd immunity thresholds, while a BDBV Ebola vaccine enters Phase 1 trials to address an outbreak in DRC—highlighting stark policy-driven gaps in disease prevention.
- •Monitor state-level regulatory responses, vaccine manufacturer compliance strategies, measles outbreak trajectory, pediatric vaccination coverage rates, and potential litigation challenging the order's public health rationale.
measles mumps rubella vaccineZaire ebolavirus vaccineBundibugyo virus vaccine
→ Read original articlePolicy•STAT News•Aug 13, 2026
Opinion: How to disrupt the health misinformation business model
background ▾
- •Oxford's statin safety model provides quantified, personalized risk data (99.6% low-risk) that could directly counter misinformation, but efficacy depends on whether accurate information can reach patients through social-media-dominated information channels.
- •Health misinformation has become a scalable business model: influencers monetize patient fear by steering them away from FDA-approved drugs and toward unproven supplements, with demonstrable clinical harms (linked to increased heart attack and death rates).
- •Monitor whether healthcare institutions and platforms can develop effective counter-messaging strategies; current approaches (platform flagging, Mayo Clinic YouTube content) appear inadequate against the financial incentives driving misinformation spread.
statinsfish oil
→ Read original articlePolicy•Endpoints News•Aug 12, 2026
Four questions on new safety warnings for Neurocrine’s Vykat XR
background ▾
- •Safety concerns raised by PWS experts regarding Vykat XR side effects and potential treatment-related deaths
- •Potential trigger for FDA label revision or post-market safety investigation
- •Watch for regulatory response from FDA and any subsequent label changes or clinical guidance updates
Neurocrine BiosciencesVykat XR
→ Read original articlePolicy•STAT News•Aug 12, 2026
Vaping and cannabis hit record highs among young adults in 2025: Survey
background ▾
- •Nicotine pouch use among young adults doubled from 5% to 13% in just two years (2023–2025), coinciding with FDA authorizations of new flavors and lower-risk marketing claims for products like Zyn
- •Vaping prevalence tripled since tracking began in 2017 (to 19%), while cannabis use remains near all-time highs (29%) with record daily use (12%), suggesting major shifts in substance-use patterns among young adults
- •FDA's recent decisions to authorize fruit-flavored vapes and allow reduced-risk claims for nicotine pouches are already generating pushback from public health experts warning of expanded market access and youth appeal, signaling potential regulatory and policy conflict ahead
nicotine vapescannabisnicotine pouches
→ Read original articlePolicy•STAT News•Aug 12, 2026
Trump administration’s new ‘treatment first’ addiction toolkit emphasizes faith, abstinence
background ▾
- •The Trump administration's toolkit explicitly opposes harm reduction and housing-first strategies, instead mandating abstinence-focused treatment as prerequisite to housing and services, marking a significant ideological reversal from Biden-era policy
- •Medications for opioid use disorder (methadone, buprenorphine) receive only passing mention despite being evidence-based overdose prevention tools, signaling potential funding and regulatory pressure on medication-assisted treatment programs
- •Watch for: federal grant redirections toward abstinence/faith-based programs, potential regulatory changes affecting MOUD prescribing or telehealth access, and real-world outcome data comparing abstinence-first vs. harm reduction approaches in pilot communities
methadonebuprenorphine
→ Read original articleMarket Access
Market Access•Endpoints News•Aug 12, 2026
Eli Lilly files first lawsuits over retatrutide 'black market'
background ▾
- •Eli Lilly is taking legal action against unauthorized distributors of retatrutide, marking an industry effort to control black market supply of high-demand investigational drugs
- •Retatrutide's popularity in illicit markets reflects broader demand for GLP-1 based weight loss agents ahead of formal approval, creating liability and safety risks for the company
- •Watch for outcomes of these lawsuits and whether other pharma companies adopt similar enforcement strategies; also monitor retatrutide's regulatory timeline and commercial launch plans
Eli Lillyretatrutide
→ Read original articleMarket Access•Endpoints News•Aug 12, 2026
AbCellera, Silence and InduPro all raise significant funding
background ▾
- •AbCellera secured $200M in funding following Phase 2 trial success
AbCelleraSilence TherapeuticsInduPro
→ Read original articleMarket Access•Endpoints News•Aug 12, 2026
Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
background ▾
- •Boulevard Bio raised $65M and acquired Vera Therapeutics' IgAN program, signaling strategic focus on immunology with a commercial-stage indication
- •IgAN is an increasingly attractive market segment following recent competitive approvals and payer uptake, suggesting Boulevard Bio identified a valuable asset
Boulevard BioVera Therapeutics
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 13, 2026
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
background ▾
- •Zipalertinib-chemotherapy combination met primary PFS endpoint in first-line EGFR exon 20 NSCLC, with manageable safety profile, positioning it as direct competitor to J&J's Rybrevant ($546M H1 2026 sales) and AstraZeneca's newly acquired Zegfrovy
- •Success triggers $100 million regulatory milestone for Cullinan and sets stage for three-way market competition in previously under-served indication where J&J has dominated due to lack of alternatives
- •Monitor FDA approval decision (due Feb. 27, 2027) for second-line zipalertinib and timing of first-line NDA; watch for full PFS efficacy data and real-world uptake trajectory against entrenched bispecific competitor
Taiho PharmaceuticalCullinan TherapeuticsJohnson & JohnsonzipalertinibRybrevantLazcluze
→ Read original articleClinical Trials•Fierce Biotech•Aug 12, 2026
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
background ▾
- •Aardvark terminated phase 3 trials for ARD-101 (Prader-Willi syndrome) and ARD-201 after FDA clinical hold, with no plans to resume the studies in their current design
- •FDA clinical hold was triggered by reversible cardiac safety signals observed in healthy volunteers, a significant liability for a metabolic/endocrine disorder program
- •Company is analyzing unblinded phase 3 data in Q3 to inform a redesigned development strategy; watch for regulatory guidance and potential trial redesign announcement by year-end 2024
Aardvark TherapeuticsWilliam BlairARD-101ARD-201
→ Read original articleClinical Trials•Fierce Biotech•Aug 12, 2026
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
background ▾
- •DT120 demonstrated a 5.4-point placebo-adjusted reduction on HAM-A at week 12 following a single psychedelic session—substantially exceeding the historical ~5-point threshold previously considered maximal in anxiety pivotal trials
- •Back-to-back Phase 3 wins in both depression and anxiety with a single-dose, long-acting mechanism represent clinically significant data that positions DT120 as a potential first-in-class psychedelic therapeutic
- •Watch for Panorama trial readout next month; Definium's FDA dialogue appears constructive, but regulatory pathway for psychedelics remains evolving and approval is not assured despite compelling data
Definium TherapeuticsEli LillyAtaiBeckleyDT120 ODTLSDCymbalta
→ Read original articleClinical Trials•Fierce Biotech•Aug 12, 2026
AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report
background ▾
- •AI clinical monitoring agents can reduce oncology trial timelines by ~18 weeks and direct operating costs by $4.4-5.6 million per trial, with documented 64-82× ROI depending on phase
- •For a large pharma sponsor deploying this technology across a 20-50 indication portfolio, incremental eNPV could reach $226-565 million, addressing a critical bottleneck in clinical development timelines
- •This represents the first eNPV modeling of agentic AI in drug development using actual deployment data; adoption metrics and real-world validation across non-oncology indications will determine whether these projections materialize
MedableTufts Center for the Study of Drug Development
→ Read original articleClinical Trials•STAT News•Aug 12, 2026
Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says
background ▾
- •WHO has recommended Merck's Ervebo for Phase 3 testing against Bundibugyo Ebola despite it being developed for a different Ebola species, based on emerging evidence of potential cross-protection
- •The Bundibugyo outbreak is tracking toward becoming the largest Ebola epidemic on record, with 4,500+ confirmed cases and 2,060 deaths as of the reporting date
- •Regulatory approval in DRC is imminent but competing policy tension exists: WHO-led trial approach versus DRC's stated interest in general vaccine rollout outside clinical trials; vaccine supply availability remains uncertain given 500,000-dose global stockpile
MerckUniversity of OxfordDoctors Without BordersErvebo
→ Read original article